DURECT Corporation (DRRX)

0.6851 +0.0364 (+5.61%) At close: 04:00PM EDT

DURECT Corporation

10260 Bubb Road
Cupertino, CA 95014-4166
United States
408 777 1417
https://www.durect.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 78

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. James E. Brown D.V.M.	Co-Founder, CEO, Pres & Director	859.68k	N/A	1957
Ms. Judy R. Joice	Sr. VP of Operations & Corp. Quality Assurance	436.99k	102.25k	1957
Dr. Norman L. Sussman M.D.	Chief Medical Officer	570.32k	N/A	1953
Mr. Timothy M. Papp	Chief Financial Officer	N/A	N/A	N/A
Ms. Jian Li M.B.A.	Interim Principal Accounting Officer, Sr. VP of Fin., Corp. Controller & Sec.	N/A	N/A	1970
Dr. Andrew R. Miksztal Ph.D.	VP of Pharmaceutical R&D and Principal Scientist	N/A	N/A	N/A
Mr. Steve Helmer J.D.	VP & Chief Patent Counsel	N/A	N/A	N/A
Dr. WeiQi Lin	Exec. VP of R&D and Principal Scientist	N/A	N/A	N/A
Dr. Su Il Yum Ph.D.	Exec. Officer	N/A	N/A	1939

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Corporate Governance

DURECT Corporation’s ISS Governance QualityScore as of July 31, 2022 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.